BIO Submits Comments on Medicare CY 2020 Part D Draft Call Letter
March 20, 2019
BIO submitted comments on the Centers for Medicare and Medicaid Service’s Advance Notice of Methodological Changes for Calendar Year (CY) 2020 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2020 Draft Call Letter.
BIO supports CMS’s commitment to improving the quality and delivery of care in the MA and Part D programs. It’s critically important to ensure these programs advance patient access to timely and appropriate treatment, particularly for prescription drugs and vaccines. BIO provided comments on how to update and clarify the policies and provide greater access to patients while mitigating OOP costs.
Download Full Comments Below
FINAL BIO CY 2020 Draft Call Letter Comments 1 March 2019
The Biotechnology Innovation Organization appreciates the opportunity to comment on the Center for Medicare and Medicaid Services’ Information Collection Request on the Part C and Part D Medicare Prescription Payment Plan Model Documents.
We are writing to express our strong support for the bipartisan Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act). The legislation, which was introduced by Reps. John Joyce (R-PA) and Wiley Nickel (D-NC) in September,1 corrects a…
BIO submitted comments on the Centers for Medicare and Medicaid Service’s Advance Notice of Methodological Changes for Calendar Year (CY) 2020 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2020 Draft Call Letter.
BIO supports CMS’s commitment to improving the quality and delivery of care in the MA and Part D programs. It’s critically important to ensure these programs advance patient access to timely and appropriate treatment, particularly for prescription drugs and vaccines. BIO provided comments on how to update and clarify the policies and provide greater access to patients while mitigating OOP costs.